DelveInsight’s “Pseudomonas Aeruginosa Infection Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pseudomonas Aeruginosa Infection market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers the emerging Pseudomonas Aeruginosa Infection drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Pseudomonas Aeruginosa Infection treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pseudomonas Aeruginosa Infection: An Overview
Pseudomonas Aeruginosa Infection is caused by a bacterium from the genus Pseudomonas. It is an aerobic gram-negative bacterium and is characterized by motile, non-spore-forming rods that are oxidase-positive and lactose nonfermenters. This bacteria is commonly found in the environment, like in soil and water. The infection, caused by P. aeruginosa, is common, with a significant burden of infection in hospitalized patients.
Pseudomonas Aeruginosa infection can develop in various anatomic sites, including skin, subcutaneous tissue, bone, ears, eyes, urinary tract, lungs, and heart valves. The variation in the sites depends on the site of entry and the patient’s vulnerability. The first sign in hospitalized patients may be overwhelming gram-negative sepsis.
Diagnosis of Pseudomonas infections depends on culturing the organism from the site of infection: blood, skin lesions, drainage fluid, urine, CSF, or eye. Susceptibility testing is also performed, wherein localized infection may produce a fruity smell of newly mown grass, and pus may be greenish.
Pseudomonas Aeruginosa Infection Market Key Facts
As per the data by the Centers for Disease Control and Prevention (CDC), there are an estimated 51,000 healthcare-associated pseudomonas aeruginosa infections cases that occur each year in the United States. Also, in 2019, multidrug-resistant P. aeruginosa caused an estimated 32,600 infections among hospitalized patients in the United States.
The data by Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (2019) reported that the annual incidence rate of Pseudomonas aeruginosa infections among MHS beneficiaries treated at a military treatment facility (MTF) was found to be approximately 30.6 per 100,000 persons per year.
According to the European Centre for Disease Prevention and Control (ECDC, 2018), about 32% of the P. aeruginosa isolates reported, were resistant to at least one of the antimicrobial groups under regular surveillance (piperacillin ± tazobactam, fluoroquinolones, ceftazidime, aminoglycosides, and carbapenems) in Europe.
Pseudomonas Aeruginosa Infection Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Pseudomonas Aeruginosa Infection market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Pseudomonas Aeruginosa Infection market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Pseudomonas Aeruginosa Infection Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Pseudomonas Aeruginosa Infection epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Pseudomonas Aeruginosa Infection Epidemiology, Segmented as –
Total Incidence of Pseudomonas Aeruginosa Infection in the 7MM [2019–2032]
Treated cases of Pseudomonas Aeruginosa Infection in the 7MM [2019–2032]
Antimicrobial Resistance-specific Incidence of Pseudomonas Aeruginosa Infection in the 7MM [2019–2032]
Hospital Acquired incidence cases of Pseudomonas Aeruginosa Infection in the 7MM [2019–2032]
Disease-specific Incidence of Pseudomonas Aeruginosa Infection in the 7MM [2019–2032]
Pseudomonas Aeruginosa Infection Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pseudomonas Aeruginosa Infection market or expected to be launched during the study period. The analysis covers the Pseudomonas Aeruginosa Infection market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the Pseudomonas Aeruginosa Infection market drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the Pseudomonas Aeruginosa Infection drugs based on their sale and market share.
The report also covers the Pseudomonas Aeruginosa Infection pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Pseudomonas Aeruginosa Infection Market Will Evolve and Grow by 2032 @
Pseudomonas Aeruginosa Infection Therapeutics Analysis
Several major pharma and biotech companies are working in the Pseudomonas Aeruginosa Infection therapeutics market. Currently, Amrata Pharmaceuticals is leading the therapeutics market with its Pseudomonas Aeruginosa Infection drug candidates in the most advanced stage of clinical development.
Pseudomonas Aeruginosa Infection Companies Actively Working in the Therapeutics Market Include
And Many Others
Emerging and Marketed Pseudomonas Aeruginosa Infection Therapies Covered in the Report Include:
AP PA02: Armata Pharmaceuticals
AB 569: Archs Biopharma
Fetroja (cefiderocol): Shionogi
BX004-A: BiomX, Inc.
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pseudomonas Aeruginosa Infection Competitive Intelligence Analysis
4. Pseudomonas Aeruginosa Infection Market Overview at a Glance
5. Pseudomonas Aeruginosa Infection Disease Background and Overview
6. Pseudomonas Aeruginosa Infection Patient Journey
7. Pseudomonas Aeruginosa Infection Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Pseudomonas Aeruginosa Infection Treatment Algorithm, Current Treatment, and Medical Practices
9. Pseudomonas Aeruginosa Infection Unmet Needs
10. Key Endpoints of Pseudomonas Aeruginosa Infection Treatment
11. Pseudomonas Aeruginosa Infection Marketed Therapies
12. Pseudomonas Aeruginosa Infection Emerging Drugs and Latest Therapeutic Advances
13. Pseudomonas Aeruginosa Infection Seven Major Market Analysis
14. Attribute Analysis
15. Pseudomonas Aeruginosa Infection Market Outlook (In US, EU5, and Japan)
16. Pseudomonas Aeruginosa Infection Access and Reimbursement Overview
17. KOL Views on the Pseudomonas Aeruginosa Infection Market
18. Pseudomonas Aeruginosa Infection Market Drivers
19. Pseudomonas Aeruginosa Infection Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
India Healthcare Market Outlook
“India Healthcare Outlook Report, 2023,” provides comprehensive insights into the healthcare scenario, regulatory policies, and reimbursement landscape in India. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this, the report also provides a brief look into the trends and segmentation of the Indian pharmaceutical and medical devices market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States